RxDoctor Payments Data

Robert Adlerstein

Family · Las Vegas, NVNPI 1255085445

Payments from drug & device makers

$6,276in general payments, 2019–2025

Across 395 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$1K
  • Mallinckrodt Hospital Products Inc.$488
  • Novartis$470
  • Amgen$466
  • ANI Pharmaceuticals, Inc.$428
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,17798%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,276 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$105,118
Medicare patients
160
Services billed
9,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cimzia (2 Pack)Certolizumab Pegol30$303,352
Humira(Cf) PenAdalimumab24$239,095
Enbrel SureclickEtanercept17$136,255
RinvoqUpadacitinib12$122,698
OrenciaAbatacept13$88,375
Restasis MultidoseCyclosporine11$7,041
Hydroxychloroquine Sulfate195$6,495
MethotrexateMethotrexate Sodium163$3,815
Lidocaine29$2,928
Diclofenac Sodium59$1,969
Celecoxib24$1,457
Leflunomide26$1,326
Colchicine16$1,270
Prednisone176$1,084
Sulfasalazine34$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$1,328$303,35230 claims
AbbVieRinvoq, Restasis Multidose$1,459$129,73823 claims
E.r. Squibb & Sons, L.L.C.Orencia$415$88,37513 claims
Scilex Pharmaceuticals Inc.Colchicine$14$1,27016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →